Compare Freeport-McMoRan Inc (FCX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Recursion Pharmaceuticals Inc — how do they compare? Freeport-McMoRan Inc trades at $58.56 (market cap $87.65B), while Recursion Pharmaceuticals Inc trades at $3.15 (market cap $1.75B). The key difference: Freeport-McMoRan Inc is far larger — about 50.1× Recursion Pharmaceuticals Inc's market cap, and Freeport-McMoRan Inc pays a 0.98% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| FCX | RXRX | |
|---|---|---|
Market Cap | $87.65B | $1.75B |
Sector | Basic Materials | Health |
52-Week High | $71.73 | $6.79 |
52-Week Low | $35.34 | $2.84 |
Enterprise Value | $94.31B | $1.17B |
Dividend Yield | 0.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freeport-McMoRan (FCX) trades at $61.97, up 3.33% with a bearish technical signal despite three consecutive quarterly earnings beats. The copper miner shows improving fundamentals with revenue growth to $25.92B and net income of $2.20B in 2025, supported by strong copper demand. Analyst consensus remains bullish with a $72.94 price target, though the stock faces technical resistance near $63-64 levels.
FCX presents a compelling value proposition with expanding profit margins and strategic positioning in the copper market, though investors face volatility risks from commodity price fluctuations and ongoing negative cash flow trends. The company's expansion pipeline and dividend payments provide additional shareholder value drivers.
Recursion Pharmaceuticals (RXRX) trades at $3.175, down 4.94% on the day, reflecting ongoing investor concerns about profitability. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal significant losses with a net income margin of -851.51% despite recent earnings beats. Analyst consensus is mixed with 40% buy ratings but a $7.83 price target suggesting substantial upside potential from current levels.
The outlook remains speculative given the company's heavy losses and cash burn, though AI-driven drug discovery platform and recent clinical progress offer long-term potential. Key risks include prolonged unprofitability, intense biotech competition, and dependence on successful drug development. The stock presents high-risk/high-reward characteristics suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
